Piper Sandler raised the firm’s price target on Dentsply Sirona to $35 from $31 and keeps a Neutral rating on the shares. While Dentsply Sirona has a path towards modest EPS growth by virtue of cost-cutting and restructuring, Piper has bigger picture concerns regarding the positioning of its portfolio towards the higher-end of the dental market where volume growth is slower than the value segment and has greater risk of future price pressure, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on XRAY:
- Dentsply Sirona to Present at J.P. Morgan Healthcare Conference, Provides Update on Anticipated Full Year 2023 Results
- Dentsply Sirona sees double-digit adjusted EPS growth in 2024
- Dentsply Sirona sees 2023 adjusted EPS $1.80-$1.85, consensus $1.82
- Dentsply Sirona to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Dentsply Sirona Declares Quarterly Cash Dividend
